A recent randomized clinical trial from Johns Hopkins University highlights the emerging potential of psilocybin-assisted therapy as a novel approach to smoking cessation. In the study, 82 adult smokers—most of whom had previously struggled to quit—were assigned either a standard nicotine patch regimen or a single, supervised high dose of psilocybin, with both groups receiving 13 weeks of cognitive behavioral therapy (CBT).
At six months, the results were striking: participants in the psilocybin group were more than six times as likely to remain abstinent from smoking compared to those using nicotine patches, with 17 individuals smoke-free versus just four in the control group. These outcomes suggest a substantially higher efficacy than many existing cessation tools, which often yield modest long-term success rates.
Unlike traditional pharmacotherapies that target nicotine receptors to reduce withdrawal and cravings, psilocybin appears to work through a fundamentally different mechanism. Researchers believe it facilitates shifts in cognition, self-perception, and behavioral patterns, potentially enhancing psychological flexibility and reinforcing the therapeutic effects of CBT. The drug sessions were conducted in controlled settings with psychological support, underscoring the importance of context and integration in psychedelic-assisted treatments.
Despite these promising findings, limitations remain. The study sample was relatively small and lacked diversity, and the absence of a placebo control introduces potential bias. Larger, more rigorous trials are underway to confirm efficacy, optimize protocols, and assess scalability.
Overall, this research represents a compelling step forward in addiction treatment, positioning psilocybin as a potentially transformative tool in addressing tobacco dependence—one of the leading causes of preventable death.
Full Article: https://www.wwno.org/npr-news/2026-03-10/a-dose-of-psilocybin-helps-smokers-quit-in-new-study?utm